

# CLINICAL REVIEW

## Ebola virus disease

Nicholas J Beeching *senior lecturer (honorary consultant)*<sup>1,2</sup>, Manuel Fenech *specialist trainee in infectious diseases*<sup>2</sup>, Catherine F Houlihan *clinical research fellow*<sup>3</sup>

<sup>1</sup>Liverpool School of Tropical Medicine, Royal Liverpool University Hospital, Liverpool, UK; <sup>2</sup>Royal Liverpool University Hospital, Liverpool, UK;

<sup>3</sup>London School of Hygiene and Tropical Medicine, London, UK

**This clinical review has been developed for *The BMJ* in collaboration with BMJ Best Practice, based on a regularly updated web/mobile topic that supports evidence-based decision making at the point of care. To view the complete and current version, please refer to the Ebola virus infection topic on the BMJ Best Practice website.**

Ebola virus disease is a severe, often fatal, zoonotic filovirus infection (fig 1⇓). There are five species: *Zaire ebolavirus*, *Sudan ebolavirus*, *Tai Forest ebolavirus*, *Bundibugyo ebolavirus*, and *Reston ebolavirus*.<sup>1</sup>

*Zaire ebolavirus* is responsible for the current outbreak in west Africa, the largest outbreak since the virus was discovered in 1976 (fig 2⇓).

Transmission occurs by close contact with body fluids of infected patients. The incubation period after infection is usually 5-9 days, with a range of 1-21 days in 95% or more of patients,<sup>2,3</sup> and patients are not considered infectious until they develop symptoms. The initial presentation is non-specific, which makes early clinical diagnosis difficult. Human infection carries a high case fatality rate depending on the species of Ebola virus and quality of supportive care available.<sup>4,5</sup>

Ebola virus infection (formerly Ebola haemorrhagic fever) is part of a group of diseases known as viral haemorrhagic fevers.<sup>6</sup>

### What causes it?

The virus is thought to be initially acquired by exposure to body fluids or tissue from infected animals, such as bats and non-human primates; however, the natural reservoir and mode of transmission to humans has not been confirmed.<sup>7,8</sup> Laboratory testing of reservoir competence shows that successful infection is possible in bats and rodents, but not in plants or arthropods.<sup>9-12</sup>

Animal to human transmission may occur during hunting and consumption of the reservoir species or infected non-human primates. The practice of butchering or eating bush meat or food contaminated with bat faeces (three species of tree roosting bats have been implicated as a reservoir) is also thought to contribute.

Human to human transmission occurs through contact with body fluids from infected patients.<sup>13</sup> In early epidemics, the re-use of non-sterile injections was responsible for many healthcare

associated transmissions.<sup>14</sup> However, although this remains a risk, most cases result from close physical contact or contact with body fluids (such as sweat, blood, faeces, vomit, saliva, genital secretions, urine, and breast milk) of infected patients. In a study of viral shedding in various body fluids, Ebola virus was isolated from saliva, breast milk, stool, tears, and semen up to 40 days after the onset of illness,<sup>15-17</sup> confirming the possibility of delayed sexual transmission. Virus may be found in urine during recovery, and the duration of this phenomenon needs further study.<sup>18</sup>

Infection through inhalation is possible in non-human primates, but there is no evidence for airborne transmission in humans.<sup>19</sup>

Outside endemic areas, Ebola virus infection is rare and is usually imported.<sup>20</sup> Travellers from affected areas, and laboratory scientists and others working with potentially infected materials and animals, are at high risk.

### What is the pathophysiology of this infection

Although there have been major advances in elucidating the pathogenesis of Ebola virus infection, most of the studies were performed in non-human primate and rodent models.<sup>8</sup> This is because of the difficulties in conducting human studies in poorly resourced settings where these infections naturally occur.

The virus genome consists of a single 19 kb strand of negative sense RNA with seven viral genes that are transcribed by the viral RNA dependent RNA polymerase present in the virion. The single strand of RNA is covered by helically arranged viral nucleoproteins NP and VP30, which are linked by matrix proteins VP24 and VP4 to the lipid bilayer that coats the virion.<sup>21</sup>

Tissue invasion occurs through infected fluid coming into contact with breaks in the mucosa or skin. This can occur with animal to human or human to human transmission. Monocytes, macrophages, and dendritic cells are the preferred replication sites for filoviruses on initial infection. Infected cells migrate to the regional lymph nodes, liver, and spleen, thereby disseminating the infection. Ebola virus has a wide cell tropism and can infect a variety of cell types.<sup>8,21</sup> It also has the

**The bottom line**

- Ebola virus disease is a severe, often fatal, zoonotic infection caused by a virus of the Filoviridae family (genus *Ebolavirus*)
- Human to human transmission occurs through contact with body fluids from infected patients. The incubation period after infection is 1-21 days and patients are not considered infectious until they develop symptoms
- Initial stages of infection are non-specific, which makes the differential diagnosis broad. A history of exposure and clinical suspicion of infection should prompt isolation
- Management is currently focused on supportive care and infection control. Healthcare workers should familiarise themselves with local guidance
- Case fatality rates range from 30% to 90%
- Because of the high likelihood of infected people travelling, all countries should have tested and practised protocols ready for screening and managing patients

remarkable ability to modulate the expression of genes involved in the host immune response, causing lymphocyte apoptosis and attenuation of the protective effects of interferon.<sup>22 23</sup>

The host immune response is crucial and dictates the outcome of infection. Progression to severe disease occurs when the virus triggers expression of a host of pro-inflammatory cytokines, including interferons; interleukins (ILs) such as IL-2, IL-6, IL-8, and IL-10; interferon inducible protein; and tumour necrosis factor  $\alpha$  (TNF- $\alpha$ ).<sup>8-24</sup> This causes endothelial activation and reduced vascular integrity, release of tissue factor (with associated onset of coagulopathy), and increased nitric oxide levels (with associated hypotension).<sup>25</sup> Thrombocytopenia is most commonly caused by loss of platelets from damaged tissue or more generalised virus induced disseminated intravascular coagulation, where coagulation factors are depleted.<sup>26</sup>

Disseminated intravascular coagulation, along with acute hepatic impairment, predisposes the patient to bleeding complications. Other complications of severe disease include acute kidney injury, hepatitis, and pancreatitis.<sup>21</sup> An early antibody response, along with reduced lymphocyte depletion, is associated with effective viral clearance and survival.<sup>16</sup>

The development of shock is still not well understood. Many factors may contribute, including bacterial sepsis, possibly through gut translocation of bacteria; a direct effect of the virus; disseminated intravascular coagulation; and haemorrhage.<sup>23</sup>

## How are people at risk identified?

Ebola virus infection is transmitted mainly through close physical contact with infected patients. There is no evidence of a risk of infection before symptoms develop, but late diagnosis delays effective patient isolation, allowing for potential transmission of the infection among contacts. Screening and active case finding are therefore essential to avoid or stop an epidemic.

Early diagnosis hinges on identifying patients who are at risk. Case definitions developed by WHO and the US Centers for Disease Control and Prevention (CDC) are based on a history of exposure and clinical evidence of illness (for example, fever, headache, and myalgia). In the current epidemic areas, history of exposure is now less useful.

Screening ensures the quick identification of potential cases that need immediate isolation and investigation. People who are asymptomatic and have epidemiological risk factors may need to be monitored (for example, twice daily temperature readings) for the duration of the incubation period, depending on their risk of exposure. This ensures rapid recognition of symptoms and immediate isolation.

## Contacts

Contacts of infected patients (including healthcare workers and household contacts) are at risk of infection if they were exposed

to the patient's body fluids without protective equipment within the past 21 days.<sup>2 3</sup> Brief interactions, such as walking past a person or moving through a hospital, do not constitute close contact.

Epidemiological risk factors are divided into high risk, some risk, low (but not zero) risk, and no identifiable risk categories.

A contact is defined by WHO as someone who has slept in the same household as a patient; had direct physical contact with the patient during the illness or at the funeral; touched the patient's body fluids, clothes, or bed linens during the illness; or been breast fed by the patient (babies).<sup>27</sup>

## What infection prevention and control measures are used?

Boxes 1 and 2 list infection prevention and control measures for healthcare workers and people living in affected areas. If infection is suspected on the basis of initial screening, immediate isolation is warranted before any further investigations. This is crucial to reduce contact with other patients and healthcare workers while the patient is being investigated. Isolation measures should be continued until the patient has tested negative.<sup>28</sup>

## Personal protective equipment

The highest risk facing healthcare workers when looking after infected patients is inadvertently touching their own faces or neck under the face shield during patient care, and removing (doffing) personal protective equipment (PPE; shown in fig 3).<sup>30</sup>

Healthcare workers should understand the following basic principles of using PPE:

**Donning**—PPE must be donned correctly in the proper order before entering the patient care area. Because PPE cannot be adjusted while in the patient care area, care should be taken to ensure it is as comfortable as possible before entering and that no skin is exposed. Donning activities must be directly observed by a trained observer and a final check performed before entering the patient care area

**During patient care**—PPE must remain in place and be worn correctly for the duration of exposure to potentially contaminated areas. PPE should not be adjusted during patient care. Healthcare workers should regularly disinfect gloved hands using an alcohol based hand rub or chlorinated water, particularly after handling body fluids. If there is a partial or total breach in PPE (such as gloves separating from sleeves to leave exposed skin, a tear in an outer glove, or a needlestick) during patient care, the healthcare worker must move immediately to the doffing area to assess the exposure and implement the facility exposure plan, if indicated

**Doffing**—Removal of used PPE is a high risk process that requires a structured procedure, a trained observer, and a

**Box 1: Infection control measures for healthcare workers**

- Wear protective clothing
- Practise proper infection control and sterilisation measures
- Isolate suspected patients from each other (if possible), and patients with confirmed disease from those with suspected disease
- Avoid direct contact with bodies of people who have died from Ebola, or suspected Ebola. During epidemics, avoid direct contact with any dead body
- Notify health officials if you have direct contact with the body fluids of an infected patient

**Box 2: Infection control measures for people in affected areas**

- Practise careful hygiene (for example, wash hands with soap and water, alcohol based hand sanitiser, or diluted chlorine)
- Avoid contact with body fluids
- Do not handle items that have come into contact with an infected person's body fluids (such as clothes, medical equipment, and needles)
- Avoid funeral or burial rituals that require handling of the body of someone who has died from proven or suspected Ebola
- Avoid contact with non-human primates and bats, including body fluids or raw meat prepared from these animals
- Avoid hospitals in west Africa in which infected patients are being treated
- Returning travellers, including healthcare workers, should follow national policy for surveillance and should monitor their health for 21 days and seek medical attention if symptoms develop, especially fever

designated area for removal to ensure protection. PPE must be removed slowly and deliberately in the correct sequence to reduce the possibility of self contamination or other exposure. A stepwise process should be developed and used during training and daily practice.<sup>29</sup>

The importance of a “buddy” when inside the patient care area, and during donning and doffing, to ensure safe practice cannot be overstated, together with guidance from independent monitors if available.

## What other measures are needed if Ebola virus disease is suspected?

If infection is suspected, the patient should be isolated and all healthcare workers in contact with the patient should wear personal protective equipment.

Contact tracing (family, friends, and work colleagues) is essential. People who have been exposed to Ebola virus within the past 21 days and who are asymptomatic need to be monitored for the duration of the incubation period with twice daily temperature readings to ensure rapid recognition of symptoms. If symptoms are detected immediate isolation is essential.<sup>30</sup>

Healthcare workers suspected of being infected should be isolated and treated in the same way as any other patient until a negative diagnosis is confirmed.<sup>31</sup> If exposure to body fluids from a patient with suspected infection has occurred, the person should immediately wash affected skin surfaces with soap and water and irrigate mucous membranes with copious amounts of water.

The patient's home and any personal belongings that might have been contaminated (such as clothes, linens, eating utensils, and medical material) should be disinfected or disposed of (usually by incineration). In epidemic areas, the patient's home is sprayed with 0.5% chorine solution.

## What are the clinical features?

The case definition for Ebola virus infection is very broad and includes a long list of possible differential diagnoses (fig 4).<sup>3</sup>

## History

The initial assessment of a patient with suspected Ebola hinges on two main factors: epidemiological risk (for example, living or working in, or arrival from, an endemic area such as west Africa in the past 21 days) and presence or history of a fever in the past 24 hours. Apart from healthcare workers, people who work with primates or bats from endemic areas or with high risk clinical samples are also at high risk.

A detailed history helps to clarify the level of risk for infection and to assess the possibility of other causes of an acute febrile syndrome (fig 5).<sup>32</sup> Because malaria is still the most common cause of febrile illness in returning travellers, the presence of risk factors for acquiring malaria should be assessed (for example, living or working in, or arriving from, an endemic area; inadequate or absent chemoprophylaxis; not using insecticides or bed nets).<sup>36</sup> Infection control risk should be assessed. Having determined that a patient may be infected, the doctor needs to determine how infectious the patient currently is. For example, the absence of vomiting or diarrhoea reduces the risk of transmission, whereas uncontrolled diarrhoea greatly increases the risk.

Precautionary isolation procedures and use of PPE are mandated in symptomatic patients who may be at risk of infection until the infection is confirmed or excluded. It is extremely important to minimise the risk of transmission while investigating patients (see later).<sup>28 37</sup>

## Symptoms

There are typically three phases of illness, starting with a few days of non-specific fever, headache, and myalgia, followed by a gastrointestinal phase in which diarrhoea and vomiting, abdominal symptoms, and dehydration are prominent. In the second week, the patient may recover or deteriorate, with a third phase of illness including collapse, neurological manifestations, and bleeding, which is often fatal.<sup>38</sup>

The most common symptoms reported between symptom onset and case detection in the 2014 outbreak were fever (87.1%), fatigue (76.4%), loss of appetite (64.5%), vomiting (67.6%), diarrhoea (65.6%), headache (53.4%), abdominal pain (44.3%), and unexplained bleeding (18%) (box 3).<sup>3</sup> The high frequency of vomiting and diarrhoea means that patients are often dehydrated and hypovolaemic, particularly if they present late.

**Box 3: Typical symptoms of Ebola virus disease<sup>4</sup>**

Fever  $\geq 37.5^{\circ}\text{C}^*$   
 Fatigue  
 Nausea or vomiting  
 Diarrhoea  
 Headache  
 Abdominal pain  
 Myalgia  
 Prostration  
 Sore throat  
 Unexplained bleeding or bruising  
 Spontaneous abortion or miscarriage  
 Hiccups  
 Rash

\*The temperature threshold for "fever" level varies between different guidelines.<sup>39</sup>

Children present with similar symptoms to adults; however, younger children are reported to have more respiratory (such as cough and dyspnoea) and gastrointestinal symptoms, but less bleeding and neurological signs, than adults.<sup>40 41</sup> Anecdotally, children under 4 years present initially with more subtle symptoms before developing a fever and are often diagnosed late.

**Physical examination**

A full physical examination should be undertaken with precautionary isolation procedures and use of PPE. The aim of examination is to exclude a focus for sepsis while looking for signs of viral haemorrhagic fever (such as conjunctival injection, purpuric rash, or other signs of bleeding).

Vital signs should be taken:

**Fever ( $\geq 37.5^{\circ}\text{C}$ )**—Fever is the presenting symptom in about 90% of patients,<sup>3-42</sup> and its presence is enough to raise concern in the appropriate epidemiological context. Wide variations in body temperature are seen during the course of illness, with normothermia or hypothermia occurring in the later stages of fatal infection.<sup>40-44</sup> Some patients initially have a low grade fever with no other symptoms

**Blood pressure**—Hypotension is a feature of preterminal disease and shock. It is underdocumented in field studies, owing to a lack of measuring equipment in endemic areas<sup>43</sup>

**Pulse rate**—Bradycardia may be present in the initial stages of illness, whereas tachycardia may be seen in the later stages of fatal infections<sup>43</sup>

**Respiratory rate**—Tachypnoea, along with tachycardia, correlates with a more severe or advanced infection. It is more likely to be caused by respiratory compensation of a metabolic acidosis than respiratory involvement.<sup>43</sup>

Other possible findings include a maculopapular rash, bleeding, hiccups, hepatomegaly, lymphadenopathy, and neurological signs (box 4).<sup>43</sup>

Multi-organ dysfunction is common in advanced infection and includes acute kidney injury, pancreatitis, adrenal failure, and liver damage. Hepatitis is common, with aspartate aminotransferase (AST) higher than alanine aminotransferase (ALT), although jaundice is rare.<sup>23</sup> Renal dysfunction is common in advanced disease but can be reversed with adequate fluid resuscitation in the initial stages.<sup>23</sup> In early disease it may be caused by dehydration, but in later stages it may be a consequence of disseminated intravascular coagulation or direct damage to the kidneys by the Ebola virus.<sup>23 43</sup> Massive bleeding,

typically in the gastrointestinal tract (for example, bloody diarrhoea or melaena), is usually seen only in fatal cases.<sup>43</sup> Internal bleeding may be missed if there are no external signs. Signs that indicate severe or advanced infection include hiccups, hypotension, tachycardia, hepatomegaly, splenomegaly, confusion, and seizures.

**How is it investigated?**

All specimens should be collected according to strict protocols.

**Initial investigations**

The main confirmatory test for Ebola virus infection is a positive Ebola RT-PCR.<sup>48</sup> This test should be ordered in all patients with suspected Ebola infection while the patient is isolated. The results of RT-PCR are available 24-48 hours before those of enzyme linked immunosorbent assay (ELISA) testing. In Western settings, Ebola RT-PCR may be available only in regional or national reference laboratories that have a high level of biosafety precautions (category 4 facilities).<sup>8</sup> In epidemic settings and some European countries, category 4 laboratories are set up locally, and RT-PCR is available four hours after the sample has arrived. Viral RNA can be detected in the patient's blood by RT-PCR from day 3 to days 6-17 of symptoms. A positive result implies that the patient is potentially infectious, particularly if there is active diarrhoea, vomiting, or bleeding. If negative, the test should be repeated within 48 hours because viral load can be low and undetectable early in the illness. Negative tests should also be repeated to rule out the diagnosis (or confirm resolution of infection) if there is a strong suspicion of Ebola.<sup>31</sup> Higher viral load correlates with adverse outcome.<sup>5-49</sup> The choice of whether to test for Ebola depends on the patient's history and the risk of infection (fig 5).

Malaria is still the most common cause of fever in people who live or work in, or travellers who have returned from, an endemic area and should be ruled out.<sup>36</sup> If a malaria rapid diagnostic test is positive, malaria should be treated while keeping in mind the possibility of a dual infection. Ebola virus infection should be considered in a patient who does not respond to antimalarial therapy.

It is recommended that confirmatory tests for Ebola virus infection are performed before, or in tandem with, differentiating tests for other suspected conditions if Ebola virus infection is suspected.

**Box 4: Physical examination findings***Maculopapular rash*

- Develops early in the course of illness in 25-52% of patients,<sup>43</sup> although its occurrence has been much lower (5%) in the 2014 outbreak<sup>3</sup>
- Often described as non-pruritic, erythematous, and maculopapular
- May begin focally then become diffuse, generalised, and confluent. Some have described it as morbilliform
- May become purpuric or petechial later on in the infection in patients with coagulopathy
- May be difficult to discern in dark skinned patients

*Bleeding*

- Bleeding manifestations (such as epistaxis, bleeding gums, haemoptysis, easy bruising, conjunctival bleeding, haematuria, and oozing from injection or venipuncture sites) were present in 30-36% of infected patients in previous outbreaks,<sup>8,46</sup> but they have been reported in only 18% of patients in the 2014 outbreak<sup>3,47</sup>

*Hiccups*

- A sign of advanced infection, typically seen in the last 2-3 days of fatal infections

*Hepatomegaly or epigastric tenderness*

- Tender hepatomegaly, with the edge of the liver palpable below the rib cage, has been reported but is rare

*Lymphadenopathy*

- Enlarged lymph nodes have been reported but are rare

*Neurological signs*

- Confusion, depressed consciousness, encephalopathy, and seizures are rare but their presence indicates advanced infection

**Other investigations**

In the past, only a malaria screen and RT-PCR were recommended because of the risk to laboratory workers. However, it is now recognised that other investigations can be done safely according to recommended guidelines, as long as the laboratory is informed of the sample in advance, and the samples are correctly packaged and retained at the end in case the results are positive.<sup>28,42</sup> Local protocols should be clear about safe transport of samples to the local and referral laboratories and safe handling on receipt in the local laboratory.

Box 5 outlines additional investigations that may add valuable information to help guide further management, and that should be ordered if possible.

**How is it managed?**

The mainstay of treatment is early recognition of infection, coupled with effective isolation and best available supportive care in a hospital setting.

High case fatality rates may be related to the supportive care available in resource poor rural settings where outbreaks have occurred. They reflect the difficulties that patients in these settings have in accessing basic medical care in a healthcare structure that is overwhelmed.<sup>3,5</sup>

During the 2014 outbreak, comprehensive supportive care—including organ support in intensive care units—was available to cases imported to developed countries such as Spain, Italy, Switzerland, Germany, France, Norway, the UK, and the US.<sup>18-55</sup> Despite this, deaths still occurred because of the lack of specific effective treatments.

There is active debate about the suitability of moving patients with advanced disease and a poor prognosis to intensive care, where the risk for nosocomial infection may be high.<sup>52-57</sup> However, failure to provide full supportive care to those with suspected (not confirmed) infection may result in substandard care for these patients, who may later be shown to have a treatable disease such as malaria. Local hospital protocols should consider how this situation should be handled for patients with suspected infection before possible transfer to the intensive care unit, and for those who have already been transferred there.<sup>52-57</sup>

**Isolation and infection control**

Patients identified as being at risk of infection should immediately be isolated in a room with private bathroom facilities.

All attending healthcare personnel must wear PPE that conforms with published protocols (fig 3).<sup>29,58</sup> All contaminated materials (such as clothes and bed linens) should be treated as potentially infectious.

Specimens for laboratory investigations (such as Ebola RT-PCR, full blood count, serum creatinine and urea, liver function tests, arterial blood gases, coagulation studies, blood cultures, and investigations for other conditions such as malaria) should be collected and sent off according to local and national protocols. Judicious selection of investigations is needed to reduce the risk of transmission to laboratory workers and other healthcare personnel. Early placement of a central line (if possible) allows blood to be taken and fluids to be given while minimising the risk of needlestick injuries.

**Fluid and electrolyte replacement**

Vomiting and diarrhoea are common, so patients are often dehydrated and hypovolaemic, particularly if they present late. This is probably the cause of the high case fatality rates because essential clinical monitoring (temperature, respiratory rate, pulse rate, blood pressure, and fluid input and output) is often difficult in resource poor settings.

Oral rehydration solutions can be used for patients who can tolerate oral administration and who are not severely dehydrated. The volume of intravenous fluids needed should be assessed on the basis of the clinical examination (level of dehydration, signs of shock) and fluid losses (volume of diarrhoea or vomitus, or both). Large volumes of fluid replacement (>10 L/day) may be needed in febrile patients with diarrhoea.<sup>18</sup>

Access to point of care tests in the isolation facility means that the patient's biochemical status can be monitored more efficiently and reduces the risks associated with specimen transport.<sup>5,52</sup> Electrolyte monitoring should be performed daily. More frequent monitoring can be considered if large volumes of intravenous fluids are being given or if severe biochemical

**Box 5: Other useful investigations when diagnosing Ebola virus disease***Antigen capture enzyme linked immunosorbent assay (ELISA) testing*

A useful diagnostic test with high specificity, although it is not universally available

Most likely to give a positive result on days 3-6 of symptoms and can give widely variable results from days 7-16<sup>17</sup>

Can be used to confirm the diagnosis along with a positive reverse transcriptase-polymerase chain reaction result

*Full blood count*

Decreasing platelet count with marked lymphopenia can be seen in the initial stages of infection but is not diagnostic. This is often followed by neutrophil leucocytosis in the later stages in patients who eventually recover, along with normalisation of thrombocytopenia. Leucocytosis may persist and show immature forms

Patients with severe disease may show a progressive decline in platelet count as a manifestation of disseminated intravascular coagulation (DIC)

Haemoglobin may be low in patients with bleeding manifestations<sup>43</sup>

*Coagulation studies*

Prolonged prothrombin time or activated partial thromboplastin time is associated with more severe infection and bleeding manifestations such as DIC

D-dimer values are four times higher on days 6-8 of infection in patients who die than in those who survive<sup>50</sup>

*Renal function and serum electrolytes*

Raised serum creatinine or urea and abnormal electrolytes may indicate acute kidney injury; this may be seen at the end of the first week of infection<sup>51</sup>

Some studies found hypokalaemia (associated with vomiting and diarrhoea) in about half of cases

Hypocalcaemia has been associated with fatal infection

Haematuria and proteinuria may also be seen in severe disease

Oliguria that does not respond to fluid resuscitation is a poor prognostic sign<sup>43</sup>

*Arterial blood gases*

Arterial or venous blood lactate, pH, and bicarbonate can help identify the degree of systemic hypoperfusion and guide fluid resuscitation in acutely ill patients with signs of sepsis<sup>52</sup>

Raised lactate is a marker of tissue hypoperfusion and is an indicator of shock.

*Liver function tests*

Both ALT and AST are usually raised; most studies show that AST rises more than ALT—this is more suggestive of systemic tissue damage rather than hepatocellular injury

The AST:ALT ratio peaked at 15:1 on days 6-8 of infection in fatal cases compared with days 5:1 in non-fatal cases<sup>43-50</sup>

Bilirubin,  $\gamma$ -glutamyl transferase, and alkaline phosphatase are often slightly raised. Greatly raised ALT and severe jaundice suggests an alternative diagnosis (such as viral hepatitis)

*Serum amylase*

High concentrations have been reported in several studies and indicate the presence of pancreatitis, an indicator of severe infection<sup>43</sup>

*Blood cultures*

Negative blood cultures are helpful because they rule out other non-viral infectious causes (such as sepsis or enteric fever)

*Ebola specific IgM and IgG antibodies*

Useful in later stages of infection

IgM antibodies can appear in serum as early as day 2 after infection but results are variable up to day 9. They become negative between 30 and 168 days after symptom onset

An IgG response develops between days 6 and 18 and can persist for several years

A positive IgM or a rising IgG titre is strong evidence of recent Ebola virus infection<sup>17</sup>

*Chest radiography*

Useful in patients with respiratory symptoms

Pulmonary infiltrates are not typical of infection and suggest an alternative (or comorbid) diagnosis

May be difficult to arrange in an isolation unit and should be ordered judiciously to avoid contamination<sup>53</sup>

abnormalities are present. High blood lactate values are a reliable measure of hypoperfusion and can help guide fluid resuscitation.<sup>52</sup> In patients with anuria who do not respond to fluid resuscitation, renal replacement therapy has been used,<sup>18-59</sup> although there are no trial data to support its effectiveness.

Major bleeding is uncommon, but is seen in advanced infection that is usually fatal. When available, platelet and plasma transfusions should be given according to local protocols.<sup>60</sup>

**Symptomatic management**

The following management strategies are recommended:

**Fever and pain**—Fever and pain should be treated with paracetamol first. Opioid analgesics (such as morphine) are preferable for more severe pain. Non-steroidal anti-inflammatory drugs (including aspirin) should be avoided because of the associated increased risk of bleeding and potential for nephrotoxicity<sup>31</sup>

**Nausea and vomiting**—Oral or intravenous antiemetics (such as ondansetron and metoclopramide) are recommended<sup>31</sup>

**Hearburn, dysphagia, and upper abdominal pain**—An antacid or proton pump inhibitor (such as omeprazole) may be beneficial<sup>31</sup>

**Seizures**—Although uncommon, seizures can be seen in advanced disease and pose a risk to healthcare workers because they increase the risk of contact with the patient's body fluids. Contributing factors (such as high temperature, hypoperfusion, and electrolyte disturbances) must be recognised and corrected. A benzodiazepine can be used to abort the seizure and can be given intramuscularly or rectally if intravenous access is unavailable. An anticonvulsant (such as phenobarbital) can be given for repeated seizures<sup>31</sup>

**Agitation**—Although uncommon, agitation can occur in advanced disease. It may be associated with encephalopathy or may be a direct effect of the virus on the brain. Judicious use of a sedative (such as haloperidol or a benzodiazepine) will help to keep the patient calm and prevent needlestick injuries in healthcare workers<sup>31</sup>

**Sepsis and septic shock**—Management follows the same principles as for bacterial sepsis.<sup>61</sup> It should include broad spectrum antibiotics (such as ceftriaxone, piperacillin-tazobactam, or meropenem) in the first hour after sending blood cultures, rapid intravenous fluid resuscitation with assessment of response, appropriate airway management and oxygen administration, and monitoring of urine output preferably by urethral catheterisation. Broad spectrum antibiotics in these patients are used to target the presumed translocation of gut organisms. This is not backed by any evidence. Blood cultures are difficult to perform safely in infected patients.

In the absence of a response to initial management, inotropic support should be considered, preferably through a central venous catheter in an intensive care unit where invasive monitoring enables more aggressive correction of fluids, electrolytes, and acid-base balance.<sup>52 54</sup>

Malaria should be tested for and treated with appropriate antimalarial therapy. In endemic settings all patients in Ebola treatment centres are treated for malaria routinely.<sup>5-47</sup>

## Are there any emerging treatments?

Although experimental treatments for Ebola virus infection are under development, they have not yet been fully tested for safety or effectiveness.<sup>62 63</sup>

## Convalescent whole blood or plasma

There is limited evidence from past outbreaks that transfusion of blood from convalescent patients might be beneficial in the acute phase of infection and may reduce mortality.<sup>46 63</sup> Trials are planned.<sup>62 64</sup>

## ZMapp

The best known emerging treatment so far, ZMapp, is a combination of three humanised monoclonal antibodies targeted at three Ebola virus glycoprotein epitopes and is engineered for expression in tobacco plants.<sup>62-66</sup> Before the current 2014 outbreak, ZMapp had proved protective when given to non-human primates 24-48 hours after infection. Another study showed that the drug could rescue non-human primates when treatment was started up to five days after infection.<sup>67</sup> It has not yet been tested in humans for safety or efficacy; however, very limited stock (seven doses) was made available to infected patients during the current outbreak, and only one patient died. Despite its potential, numbers are too small to make any conclusions about the drug's safety and efficacy. More doses are not currently available to conduct larger trials, but

development is being accelerated with support from the US government.<sup>68</sup>

## TKM-Ebola

TKM-Ebola consists of a combination of small interfering RNAs that target Ebola virus RNA polymerase L, formulated with lipid nanoparticle technology. It has been shown to be protective in non-human primates and is effective against Marburg virus in guinea pigs and monkeys.<sup>62-71</sup> The US Food and Drug Administration has granted expanded access to this drug under an Investigational New Drug application. Under emergency protocols, it has been given to a small number of patients.

## Brincidofovir

Formerly known as CMX-001, brincidofovir is currently undergoing phase III trials for the treatment of cytomegalovirus and adenovirus. It also shows activity against Ebola virus *in vitro*. The drug has been used in patients with Ebola virus infection in the US under Emergency Investigational New Drug applications approved by the FDA. Trials are planned in the near future in west Africa.<sup>62-64</sup>

## Favipiravir

Formerly known as T-705, favipiravir selectively inhibits viral RNA dependent RNA polymerase. It is active against influenza viruses, West Nile virus, yellow fever virus, foot and mouth disease virus, as well as other flaviviruses, arenaviruses, bunyaviruses, and alphaviruses. The drug is approved in Japan for influenza pandemics and is effective against Ebola virus in mouse models.<sup>62-72</sup> Human trials are due to start in west Africa.<sup>64</sup>

## BCX-4430

BCX-4430 is an adenosine analogue that is active against Ebola virus in rodents. It is thought to act through the inhibition of viral RNA dependent RNA polymerase. It is active against flaviviruses, bunyaviruses, arenaviruses, and paramyxoviruses. The drug has been shown to be protective in non-human primates and rodents, even when given 48 hours after infection with filoviruses<sup>63 73</sup>; however, no human studies have been performed.

## AVI-7537

AVI-7537 consists of antisense phosphorodiamidate morpholino oligomers (PMOs) that target the Ebola virus VP24 gene. It confers a survival benefit to Ebola virus infected non-human primates.<sup>63 74</sup> AVI-6002 consists of two PMOs (AV-7537 and AV-7539, which targets the VP35 gene). AV-6002 has undergone phase I clinical studies.

## Other agents

Interferons have been used in the past, with uncertain benefit.<sup>16 63</sup> Therapeutic agents used for other diseases, such as amiodarone, clomiphene, and chloroquine, inhibit Ebola virus interactions with human cells in models, and amiodarone will shortly be trialled in west Africa.<sup>62 75</sup>

## Vaccines

Two experimental vaccines are currently undergoing trials.<sup>62 63</sup> cAd3-ZEBOV is a chimpanzee derived adenovirus vector with an Ebola virus gene inserted.<sup>76</sup> Trials are under way in the United Kingdom, United States, Switzerland, and some African countries. rVSV-ZEBOV is an attenuated vesicular stomatitis

virus with one of its genes replaced by an Ebola virus gene. Human trials have started in the US.

## What is the prognosis?

The natural clinical course of Ebola virus infection varies markedly between the different viral species and according to the level of supportive medical care available. The most lethal species is *Zaire ebolavirus*, which has a reported case fatality rate of up to 90%. The rate in the current 2014 outbreak is less than this and is estimated at 60-70%, although accurate data are biased by poor record keeping and registration.<sup>3</sup> Most epidemics have occurred in resource poor settings with little supportive care, and the case fatality rate in high income settings could be less than 40%.<sup>52</sup> Mortality is higher in younger children (<5 years) and adults over 40 years than in adolescents and young adults.<sup>3-51</sup> An observational study during an outbreak in 1995 showed a marked decrease in the case fatality rate from 93% to 69% between the initial and final phases of the outbreak.<sup>77</sup> This suggests that later cases were recognised earlier and possibly received higher quality care. Pregnant women have a high incidence of miscarriage and the infection is almost always fatal in these women.<sup>38-80</sup>

## Infection course

Patients who die tend to develop clinical signs early on in the infection, with death, usually attributed to shock and multi-organ failure, typically occurring between days 6 and 16 (median 9 days) from symptom onset.<sup>19-82</sup> Patients who eventually recover exhibit isolated fever for several days with improvement typically around days 6-11. A high viral load at presentation is correlated with mortality.<sup>5-49</sup> Biomarkers as prognostic indicators require further study.<sup>51 81</sup>

## Recovery and convalescence

Patients who live through the second week of infection have more than a 75% chance of surviving.<sup>43</sup> Patients are usually discharged from the isolation facility when they are ambulant, able to self care, have no serious symptoms (such as diarrhoea, vomiting, or bleeding), and have two negative Ebola RT-PCR results taken 48 hours apart.<sup>47</sup>

Patients who survive usually have a protracted recovery characterised by asthenia, weight loss, and migratory arthralgia. Skin desquamation and transient hair loss are also common. Late manifestations during convalescence are uncommon but include uveitis, orchitis, myelitis, parotitis, pancreatitis, hepatitis, psychosis, hearing loss and tinnitus.<sup>44</sup> The cause of these manifestations is unclear but they might be related to immune complex phenomena.

Survivors of infection probably have lifetime immunity to the same strain of Ebola virus. Such patients have therefore been invaluable in caring for those with active infections.

## What advice should patients be given during recovery?

Patients should be educated about the likely course of convalescence and the possibility of long term complications. There are no specific requirements for monitoring after discharge; however, eligible patients may be asked to donate blood from 28 days after discharge to be used in the treatment of patients with active infection.

Male patients should be reminded about the importance of using condoms to prevent sexual transmission in the three months

after resolution of infection.<sup>15-17</sup> Women should be advised not to breast feed during infection.<sup>15</sup>

Survivors and orphans of those who died from the disease face stigma and ostracism in many communities. This—along with substantial associated psychological disturbance—was reported after previous outbreaks,<sup>83 84</sup> and it is an increasing problem in the 2014 outbreak.

The authors thank Adam Mitchell, clinical editor and drug editor, BMJ Best Practice, for his extensive editorial support on this topic.

Competing interests: NJB is an author of several references cited in this monograph. NJB is partially supported by a National Institute of Health Research grant to the Health Protection Unit in Emerging Infections and Zoonoses, a partnership between the University of Liverpool, the Liverpool School of Tropical Medicine, and Public Health England.

Provenance and peer review: Not commissioned; externally peer reviewed.

This clinical review series has been developed for *The BMJ* in collaboration with BMJ Best Practice (<http://bestpractice.bmj.com>), an independent product produced by BMJ Publishing Group Limited. BMJ Best Practice comprises web/mobile topics that support evidence-based decision making at the point of care. Peer review of the content in this clinical review was carried out exclusively according to BMJ Best Practice's own, independent process (<http://bestpractice.bmj.com/best-practice/marketing/how-is-best-practice-produced.html>). This adaptation of a BMJ Best Practice topic for a clinical review in *The BMJ* uses only a portion of content from the latest available web version of BMJ Best Practice. BMJ Best Practice is updated on an ongoing basis, and the content of any BMJ Best Practice topic is expected to change periodically including subsequent to its publication as a clinical review in *The BMJ*. To view the complete and current versions of all BMJ Best Practice topics, please refer to the BMJ Best Practice website (<http://bestpractice.bmj.com>).

Content from BMJ Best Practice is intended to support, aid and supplement the expertise, discretion and judgment of licensed medical health professionals who remain solely responsible for decisions regarding diagnosis and treatment of their patients. Content from BMJ Best Practice is not intended to function as a substitute for a licensed medical health professional's judgment. BMJ Best Practice reflects evidence available to its authors and licensors prior to publication. *The BMJ* relies on its authors to confirm the accuracy of the information presented to reflect generally accepted practices. While *The BMJ* seeks to ensure BMJ Best Practice is up to date and accurate, it does not warrant that is the case. Content from BMJ Best Practice is supplied on an "as is" basis and any statements made to the contrary are void. BMJ Best Practice does not endorse drugs, diagnose patients, or recommend therapy. The full disclaimer applicable to BMJ Best Practice can be found at <http://bestpractice.bmj.com/best-practice/marketing/disclaimer.html>.

- Centers for Disease Control and Prevention. About Ebola virus disease. 2014. [www.cdc.gov/](http://www.cdc.gov/).
- WHO. Are the Ebola outbreaks in Nigeria and Senegal over? 2014. [www.who.int/](http://www.who.int/).
- WHO Ebola Response Team. Ebola virus disease in West Africa: the first 9 months of the epidemic and forward projections. *N Engl J Med* 2014;371:1481-95.
- Centers for Disease Control and Prevention. Ebola fact sheet. 2014. [www.cdc.gov/](http://www.cdc.gov/).
- Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, Sall AA, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. *N Engl J Med* 2014; published online 5 Nov. doi:10.1056/NEJMoa1411249.
- Hensley LE, Wahl-Jensen V, McCormick JB, Rubins KH. Viral hemorrhagic fevers. In: Cohen J, Powderly W, Opal S, eds. *Infectious diseases*. 3rd ed. Mosby; 2010:1231-7.
- Peters CJ, LeDuc JW. An introduction to Ebola: the virus and the disease. *J Infect Dis* 1999;179(suppl 1):9-16.
- Feldmann H, Geisbert TW. Ebola haemorrhagic fever. *Lancet* 2011;377:849-62.
- Swanepoel R, Smit SB, Rollin PE, Formenty P, Leman PA, Kemp A, et al. Studies of reservoir hosts for Marburg virus. *Emerg Infect Dis* 2007;13:1847-51.
- Peterson AT, Bauer JT, Mills JN. Ecologic and geographic distribution of filovirus disease. *Emerg Infect Dis* 2004;10:40-7.



**Additional educational resources***Resources for healthcare professionals*

- WHO. Infection control. Aide-memoire for infection prevention and control in a healthcare facility ([www.who.int/injection\\_safety/toolbox/docs/en/AideMemoireInfectionControl.pdf?ua=1](http://www.who.int/injection_safety/toolbox/docs/en/AideMemoireInfectionControl.pdf?ua=1))
- Centers for Disease Control and Prevention (CDC). Infection control for viral haemorrhagic fevers in the African healthcare setting ([www.cdc.gov/vhf/abroad/vhf-manual.html](http://www.cdc.gov/vhf/abroad/vhf-manual.html))
- WHO. Infection prevention and control guidance summary ([www.who.int/csr/resources/publications/ebola/evd-guidance-summary/en/](http://www.who.int/csr/resources/publications/ebola/evd-guidance-summary/en/))
- CDC. What is contact tracing? ([www.cdc.gov/vhf/ebola/pdf/contact-tracing.pdf](http://www.cdc.gov/vhf/ebola/pdf/contact-tracing.pdf))
- CDC. Epidemiologic risk factors to consider when evaluating a person for exposure to Ebola virus ([www.cdc.gov/vhf/ebola/exposure/risk-factors-when-evaluating-person-for-exposure.html](http://www.cdc.gov/vhf/ebola/exposure/risk-factors-when-evaluating-person-for-exposure.html))
- WHO. Steps to put on personal protective equipment (PPE) ([www.who.int/csr/disease/ebola/put\\_on\\_ppequipment.pdf?ua=1](http://www.who.int/csr/disease/ebola/put_on_ppequipment.pdf?ua=1))
- WHO. Steps to remove PPE ([www.who.int/csr/disease/ebola/remove\\_ppequipment.pdf?ua=1](http://www.who.int/csr/disease/ebola/remove_ppequipment.pdf?ua=1))
- UK Government. Gateway to UK government and Public Health England guidelines (<https://www.gov.uk/government/topical-events/ebola-virus-government-response>)
- Health Protection Scotland guidelines gateway ([www.hps.scot.nhs.uk/travel/viralhaemorrhagicfever.aspx](http://www.hps.scot.nhs.uk/travel/viralhaemorrhagicfever.aspx))
- European Centre for Disease Control and Prevention (ECDC) gateway to European guidelines and epidemiological updates ([http://ecdc.europa.eu/en/healthtopics/ebola\\_marburg\\_fever/Pages/index.aspx](http://ecdc.europa.eu/en/healthtopics/ebola_marburg_fever/Pages/index.aspx))
- Ebola Response Anthropology Platform ([www.ebola-anthropology.net/](http://www.ebola-anthropology.net/))—This platform engages with crucial sociocultural and political dimensions of the Ebola outbreak and build locally appropriate interventions

*Resources for travellers and people in affected areas*

- WHO. Ebola virus disease fact sheet ([www.who.int/mediacentre/factsheets/fs103/en/](http://www.who.int/mediacentre/factsheets/fs103/en/))
- CDC. Questions and answers on Ebola ([www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/qa.html](http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/qa.html))
- CDC. Bushmeat from Africa should not be imported into other countries ([www.cdc.gov/vhf/ebola/pdf/bushmeat-and-ebola.pdf](http://www.cdc.gov/vhf/ebola/pdf/bushmeat-and-ebola.pdf))
- WHO produce guidance for travellers. Travel and transport risk assessment ([www.who.int/csr/resources/publications/ebola/travel-guidance/en/](http://www.who.int/csr/resources/publications/ebola/travel-guidance/en/))
- CDC. Ebola—travel notices ([wwwnc.cdc.gov/travel/diseases/ebola](http://wwwnc.cdc.gov/travel/diseases/ebola))—As of 31 October 2014, the CDC recommend avoiding non-essential travel to Liberia, Guinea, and Sierra Leone, and practising enhanced precautions in Democratic Republic of the Congo
- ECDC. Travel advisories ([http://www.ecdc.europa.eu/en/healthtopics/ebola\\_marburg\\_fever/information-travellers/Pages/information-travellers.aspx](http://www.ecdc.europa.eu/en/healthtopics/ebola_marburg_fever/information-travellers/Pages/information-travellers.aspx))

- 11 Swanepoel R, Leman PA, Burt FJ, Zachariades NA, Braack LE, Ksiazek TG, et al. Experimental inoculation of plants and animals with Ebola virus. *Emerg Infect Dis* 1996;2:321-5.
- 12 Reiter P, Turell M, Coleman R, Miller B, Maupin G, Liz J, et al. Field investigations of an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: arthropod studies. *J Infect Dis* 1999;179(suppl 1):S148-54.
- 13 Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. *J Infect Dis* 1999;179(suppl 1):S87-91.
- 14 Report of an International Commission. Ebola hemorrhagic fever in Zaire, 1976. *Bull World Health Organ* 1978;56:271-93.
- 15 Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. *J Infect Dis* 2007;196(suppl 2):S142-7.
- 16 Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. *BMJ* 1977;2:541-4.
- 17 Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum JJ, Bressler D, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. *J Infect Dis* 1999;179(suppl 1):S28-35.
- 18 Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, Kluge S, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. *N Engl J Med* 2014; published online 22 Oct.
- 19 Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. *Lancet Infect Dis* 2004;4:487-98.
- 20 Beeching NJ, Fletcher TE, Hill DR, Thomson GL. Travellers and viral haemorrhagic fevers: what are the risks? *Int J Antimicrob Agents* 2010;36(suppl 1):S26-35.
- 21 Ramanan P, Shabman RS, Brown CS, Amarasinghe GK, Basler CF, Leung DW. Filoviral immune evasion mechanisms. *Viruses* 2011;3:1634-49.
- 22 Ramanan P, Edwards MR, Shabman RS, Leung DW, Endlich-Frazier AC, Borek DM, et al. Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. *Proc Natl Acad Sci U S A* 2012;109:20661-6.
- 23 Fletcher T, Fowler RA, Beeching NJ. Understanding organ dysfunction in Ebola virus disease. *Intensive Care Med* 2014;40:1936-9.
- 24 Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagoner KD, et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. *J Virol* 2004;78:10370-7.
- 25 Zapata JC, Cox D, Salvato MS. The role of platelets in the pathogenesis of viral hemorrhagic fevers. *PLoS Negl Trop Dis* 2014;8:e2858.
- 26 Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, Lansoud-Soukate J, et al. Human asymptomatic Ebola infection and strong inflammatory response. *Lancet* 2000;355:2210-5.
- 27 WHO. Case definition for Ebola or Marburg virus disease. 2014. [www.who.int/](http://www.who.int/)
- 28 Fletcher TE, Brooks TJ, Beeching NJ. Ebola and other viral haemorrhagic fevers. *BMJ* 2014;349:g5079.
- 29 Centers for Disease Control and Prevention. Guidance on personal protective equipment to be used by healthcare workers during management of patients with Ebola virus disease in U.S. hospitals, including procedures for putting on (donning) and removing (doffing). 2014. [www.cdc.gov/](http://www.cdc.gov/)
- 30 Centers for Disease Control and Prevention. Interim guidance for monitoring and movement of persons with Ebola virus disease exposure. 2014. [www.cdc.gov/](http://www.cdc.gov/)
- 31 WHO. Clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker. 2014. <http://apps.who.int/>
- 32 Public Health England. Marburg virus disease: origins, reservoirs, transmission and guidelines. 2014. [www.gov.uk](http://www.gov.uk)
- 33 Public Health England. Crimean-Congo haemorrhagic fever: origins, reservoirs, transmission and guidelines. 2014. [www.gov.uk](http://www.gov.uk)
- 34 Public Health England. Lassa fever: origins, reservoirs, transmission and guidelines. 2014. [www.gov.uk](http://www.gov.uk)
- 35 Hartseker RA, Collares-Pereira M, Ellis WA. Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world. *Clin Microbiol Infect* 2011;17:494-501.
- 36 Mendelson M, Han PV, Vincent P, von Sonnenburg F, Cramer JP, Loutan L, et al. Regional variation in travel-related illness acquired in Africa, March 1997-May 2011. *Emerg Infect Dis* 2014;20:532-41.
- 37 Centers for Disease Control and Prevention. Case definition for Ebola virus disease (EVD). 2014. [www.cdc.gov/](http://www.cdc.gov/)
- 38 Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A. Ebola virus disease in West Africa—clinical manifestations and management. *N Engl J Med* 2014;371:2054-7.
- 39 Dananiché C, BénéT, Vanhems P. Ebola: fever definitions might delay detection in non-epidemic areas. *Lancet* 2014;384:1743.
- 40 Mupere E, Kaducu OF, Yoti Z. Ebola hemorrhagic fever among hospitalised children and adolescents in northern Uganda: epidemiologic and clinical observations. *Afr Health Sci* 2001;1:60-5.
- 41 Peacock G, Uyeki TM, Rasmussen SA. Ebola virus disease and children: what pediatric health care professionals need to know. *JAMA Pediatr* 2014; published online 17 Oct.
- 42 Public Health England. Ebola virus disease: clinical management and guidance. 2014. [www.gov.uk/government/collections/ebola-virus-disease-clinical-management-and-guidance](http://www.gov.uk/government/collections/ebola-virus-disease-clinical-management-and-guidance)
- 43 Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. *J Infect Dis* 2011;204(suppl 3):S810-6.
- 44 Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, Guimard Y, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. *J Infect Dis* 1999;179(suppl 1):S1-7.
- 45 Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A. Human infection due to Ebola virus, subtype Côte d'Ivoire: clinical and biologic presentation. *J Infect Dis* 1999;179(suppl 1):S48-53.
- 46 Roddy P, Howard N, Van Kerkhove MD, Lutwama J, Wamala J, Yoti Z, et al. Clinical manifestations and case management of Ebola hemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda, 2007-2008. *PLoS One* 2012;7:e52986.
- 47 Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, et al; KGH Lassa Fever Program; Viral Hemorrhagic Fever Consortium; WHO Clinical Response Team. Clinical illness and outcomes in patients with Ebola in Sierra Leone. *N Engl J Med* 2014;371:2092-100.
- 48 WHO. Laboratory guidance for the diagnosis of Ebola virus disease: interim recommendations. 2014. [www.who.int/](http://www.who.int/)
- 49 Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, Vincent M, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. *J Virol* 2004;78:4330-41.
- 50 Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. *J Infect Dis* 2007;196(suppl 2):S364-71.

- 51 McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, et al. Biomarker correlates of survival in pediatric patients with ebola virus disease. *Emerg Infect Dis* 2014;20:1683-90.
- 52 Fowler RA, Fletcher T, Fischer WA 2nd, Lamontagne F, Jacob S, Brett-Major D, et al. Caring for critically ill patients with Ebola virus disease. Perspectives from West Africa. *Am J Respir Crit Care Med* 2014;190:733-7.
- 53 Auffermann WF, Kraft CS, Vanairsdale S, Lyon GM 3rd, Tridandapani S. Radiographic imaging for patients with contagious infectious diseases: how to acquire chest radiographs of patients infected with the Ebola virus. *AJR Am J Roentgenol* 2014; published online 17 Nov.
- 54 Parra JM, Salmerón OJ, Velasco M. The first case of Ebola virus disease acquired outside Africa. *N Engl J Med* 2014; published online 19 Nov.
- 55 Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK, et al; the Emory Serious Communicable Diseases Unit. Clinical care of two patients with Ebola virus disease in the United States. *N Engl J Med* 2014 published online 12 Nov. doi:10.1056/NEJMoa1409838.
- 56 Decker BK, Sevransky JE, Barrett K, Davey RT, Chertow DS. Preparing for critical care services to patients with Ebola. *Ann Intern Med* 2014; published online 23 Sep.
- 57 Canadian Critical Care Society, Canadian Association of Emergency Physicians, Association of Medical Microbiology and Infectious Diseases of Canada. Ebola clinical care guidelines: guide for clinicians in Canada. 2014. <http://cccsnew.businesscatalyst.com/>.
- 58 European Centre for Disease Prevention and Control. Epidemiological update: outbreak of Ebola virus disease in West Africa. 2014. [www.ecdc.europa.eu](http://www.ecdc.europa.eu).
- 59 Connor MJ Jr, Kraft C, Mehta AK, Varkey JB, Lyon GM, Crozier I, et al. Successful delivery of RRT in Ebola virus disease. *J Am Soc Nephrol* 2014; published online 14 Nov.
- 60 Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, Gando S, et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. *J Thromb Haemost* 2013; published online 4 Feb.
- 61 Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. *Crit Care Med* 2013;41:580-637.
- 62 Bishop BM. Potential and emerging treatment options for Ebola virus disease. *Ann Pharmacother* 2014; published online 20 Nov.
- 63 WHO. Potential Ebola therapies and vaccines. 2014. <http://www.who.int/csr/resources/publications/ebola/potential-therapies-vaccines/en/>.
- 64 Gulland A. Clinical trials of Ebola therapies to begin in December. *BMJ* 2014;349:g6827.
- 65 Zhang Y, Li D, Jin X, Huang Z. Fighting Ebola with ZMapp: spotlight on plant-made antibody. *Sci China Life Sci* 2014;57:987-8.
- 66 Goodman JL. Studying "secret serums": toward safe, effective Ebola treatments. *N Engl J Med* 2014;371:1086-9.
- 67 Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. *Nature* 2014;514:47-53.
- 68 McCarthy M. US signs contract with ZMapp maker to accelerate development of the Ebola drug. *BMJ* 2014;349:g5488.
- 69 Thi EP, Mire CE, Ursic-Bedoya R, Geisbert JB, Lee AC, Agans KN, et al. Marburg virus infection in nonhuman primates: therapeutic treatment by lipid-encapsulated siRNA. *Sci Transl Med* 2014;6:250ra116.
- 70 Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. *Lancet* 2010;375:1896-905.
- 71 Choi JH, Croyle MA. Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. *BioDrugs* 2013;27:565-83.
- 72 Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. *Antiviral Res* 2009;82:95-102.
- 73 Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. *Nature* 2014;508:402-5.
- 74 Iversen PL, Warren TK, Wells JB, Garza NL, Mourich DV, Welch LS, et al. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. *Viruses* 2012;4:2806-30.
- 75 Turone F. Doctors trial amiodarone for Ebola in Sierra Leone. *BMJ* 2014;349:g7198.
- 76 Ledgerwood JE, DeZure AD, Stanley DA, Novik L, Enama ME, Berkowitz NM, et al; the VRC 207 Study Team. Chimpanzee adenovirus vector Ebola vaccine - preliminary report. *N Engl J Med* 2014; published online 26 Nov. doi:10.1056/NEJMoa1410863.
- 77 Sadek RF, Khan AS, Stevens G, Peters CJ, Ksiazek TG. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. *J Infect Dis* 1999;179(suppl 1):S24-7.
- 78 Mupapa K, Mukundu W, Bwaka MA, Kipasa M, De Roo A, Kuvula K, et al. Ebola hemorrhagic fever and pregnancy. *J Infect Dis* 1999;179(suppl 1):S11-2.
- 79 Jamieson DJ, Uyeki TM, Callaghan WM, Meaney-Delman D, Rasmussen SA. What obstetrician-gynecologists should know about Ebola: a perspective from the Centers for Disease Control and Prevention. *Obstet Gynecol* 2014; published online 8 Sep.
- 80 Association of Women's Health, Obstetric and Neonatal Nurses. Ebola: caring for pregnant and postpartum women and newborns in the United States: AWHONN practice brief number 3. *J Obstet Gynecol Neonat Nurs* 2014; published online 24 Nov. doi:10.1111/1552-6909.12518.
- 81 Leroy EM, Gonzalez JP, Baize S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. *Clin Microbiol Infect* 2011;17:964-76.
- 82 McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, et al. Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. *J Infect Dis* 2014;210:558-66.
- 83 De Roo A, Ado B, Rose B, Guimard Y, Fonck K, Colebunders R. Survey among survivors of the 1995 Ebola epidemic in Kikwit, Democratic Republic of Congo: their feelings and experiences. *Trop Med Int Health* 1998;3:883-5.
- 84 Locsin RC, Barnard A, Matua AG, Bongomin B. Surviving Ebola: understanding experience through artistic expression. *Int Nurs Rev* 2003;50:156-66.

Cite this as: *BMJ* 2014;349:g7348

## Related links

**thebmj.com**

- Get CME/CPD credits for this article

**bmj.com/archive**


Previous articles in this series

- Managing perineal trauma after childbirth (BMJ 2014;349:g6829)
- Crohn's disease (BMJ 2014; 2014;349:g6670)
- Meniere's disease (BMJ 2014;349: g6544)
- Carpal Tunnel Syndrome (BMJ 2014;349:g6437)
- Management of arteriovenous fistulas (BMJ 2014;349:g6262)

© BMJ Publishing Group Ltd 2014

## Figures

**Fig 1** Infographic on Ebola virus disease




**Fig 2** Map of Ebola virus outbreaks 1976-2014 (Centers for Disease Control and Prevention)



**Fig 3** Healthcare worker in personal protective equipment at an Ebola treatment centre in Sierra Leone, 2014 (with permission from Chris Lane, Public Health England/WHO)

Condition	Differentiating signs/symptoms	Differentiating tests
Malaria infection	<p>Most common cause of non-specific febrile illness in returning travellers</p> <p>Inadequate or no malaria chemoprophylaxis</p> <p>There are no differentiating signs and symptoms</p> <p>Malaria infection and Ebola virus infection may co-exist</p>	<p>Giemsa stained thick and thin blood smears: positive for <i>Plasmodium</i> species</p> <p>Rapid diagnostic tests: positive for <i>Plasmodium</i> species. <i>Plasmodium ovale</i> not always detected by some rapid diagnostic tests</p>
Other viral haemorrhagic fevers	<p>There are no differentiating signs and symptoms</p> <p>Epidemiological features can help differentiate between the viral haemorrhagic fevers</p> <p>Marburg virus: exposure to bats, caves, or mining<sup>32</sup></p> <p>Crimean Congo haemorrhagic fever (CCHF): animal butchering, tick bite, or exposure to animals<sup>33</sup></p> <p>Lassa fever: exposure to rats in endemic areas<sup>34</sup></p>	<p>Reverse transcriptase-polymerase chain reaction (RT-PCR): positive for infective virus</p>
Typhoid infection	<p>There are no differentiating signs and symptoms</p>	<p>Blood or stool culture: positive for <i>Salmonella enterica</i></p>
Rickettsial infections	<p>Includes murine typhus, African tick bite fever, and epidemic typhus<sup>6</sup></p> <p>Eschar is typical</p> <p>Variable lymphadenopathy or discrete rash (or both)</p>	<p>Serology: positive for <i>Rickettsia</i> species</p> <p>Eschar PCR: positive for <i>Rickettsia</i> species</p>
Dengue fever	<p>There are no differentiating signs and symptoms</p>	<p>Serology: positive IgM or IgG</p> <p>Non-structural protein (NS1) detection: positive</p> <p>RT-PCR: positive</p>
Measles	<p>Unvaccinated</p> <p>There are no differentiating signs and symptoms in prodromal phase</p> <p>Koplik's spots (red spots with bluish-white central dot) on buccal mucosa</p> <p>Rash typically starts on face and spreads craniocaudally</p>	<p>Serology: positive for measles virus</p>
Leptospirosis	<p>There are no differentiating signs and symptoms; however, a history of exposure may be helpful</p> <p>Exposure to contaminated water or soil contaminated by infected rodents<sup>35</sup></p> <p>More common in tropical climates</p>	<p>PCR: positive</p> <p>Serology: positive</p>
Seasonal influenza infection	<p>Respiratory signs and symptoms (for example, cough, nasal congestion) are more common</p>	<p>Viral culture or PCR: detection of seasonal influenza virus or viral RNA</p> <p>Full blood count: normal</p>
Gastroenteritis	<p>In the correct epidemiological context, this can present in a similar way to Ebola virus infection. However, features such as rash, conjunctival injection, and prostration are very rare in gastroenteritis</p>	<p>Stool culture, PCR, or rapid antigen testing: positive</p>
Sepsis	<p>Bacterial sepsis with an unclear origin is a common presentation in developing countries. Often turns out to be deep abdominal infection, upper urinary tract infection, endocarditis, or discitis</p> <p>Diarrhoea is often absent</p>	<p>Blood cultures: positive</p>

**Fig 4** Differential diagnosis. Confirmatory tests should be performed before, or in tandem with, differentiating tests if Ebola virus infection is suspected



**Fig 5** Diagnostic pathway for the investigation of suspected Ebola virus infection (produced by the BMJ Evidence Centre)